IDEAYA Biosciences Inc (nasdaq:IDYA) Share Price

Company Profile

Business description
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
Contact
5000 Shoreline Court
Suite 300
South San FranciscoCA94080
USA
T: +1 650 443-6209
https://www.ideayabio.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
131

Recommended

Strong demand growth and improved profit margins lead to a strong result from the sleep apnea device firm.

Shane Ponraj, CFA | 05 August 2025

Morningstar’s Greg Warren says Berkshire may have little choice but to take a hard look at this huge potential acquisition.

Joseph Taylor | 05 August 2025

A key provision of the new award is that Musk must remain in a senior leadership position at Tesla.

Seth Goldstein, CFA | 04 August 2025

Index	Last price	Change	% Change
All Ordinaries	9,028.80	106.80	1.20%
CAC 40	7,632.01	85.85	1.14%
DAX 40	23,757.69	331.72	1.42%
Dow JONES (US)	44,173.64	585.06	1.34%
FTSE 100	9,128.30	59.72	0.66%
HKSE	24,911.97	178.52	0.72%
NASDAQ	21,053.58	403.45	1.95%
Nikkei 225	40,549.54	258.84	0.64%
NZX 50 Index	12,877.04	193.00	1.52%
S&P 500	6,329.94	91.93	1.47%
S&P/ASX 200	8,770.40	106.70	1.23%
SSE Composite Index	3,614.24	30.93	0.86%